SM
MRTX

SG3 Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

SG3 Management’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-4,000
Closed -$181K – 184
2022
Q4 		$181K Buy
+4,000
New +$259K 0.03% 166
2022
Q2 		– Sell
-10,000
Closed -$822K – 931
2022
Q1 		$822K Buy
10,000
+4,500
+82% +$460K 0.02% 500
2021
Q4 		$807K Sell
5,500
-8,500
-61% -$1.32M 0.02% 533
2021
Q3 		$2.48M Buy
+14,000
New +$2.25M 0.08% 258
2020
Q4 		– Sell
-2,000
Closed -$432K – 1262
2020
Q3 		$332K Sell
2,000
-5,500
-73% -$753K 0.01% 646
2020
Q2 		$856K Buy
7,500
+2,000
+36% +$194K 0.06% 310
2020
Q1 		$423K Buy
+5,500
New +$493K 0.06% 187

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

SG3 Management's MRTX Position: Q1 2023 in Review

SG3 Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2023, closing a stake of 4,000 shares — an estimated $181K sold.

SG3 Management first reported a position in MRTX in Q1 2020 and held it in 7 quarters. The position peaked at $2.48M in Q3 2021. 221 funds tracked by Wall St. Rank hold MRTX as of Q1 2023.

  • SG3 Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • SG3 Management sold 4,000 Mirati Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $181K.
  • SG3 Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2020 and held it in 7 quarters.
  • SG3 Management's Mirati Therapeutics, Inc. Common Stock position peaked at $2.48M in Q3 2021.
  • 221 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2023.

Based on SG3 Management's 13F filing for Q1 2023, filed 15 May 2023.